Thymosin Alpha-1 returned to Category 1 under the 2026 RFK Jr. reclassification. Pharmacy-grade compounded Tα1 is now accessible in the U.S. through a structured clinical pathway for the first time.
COMPOUND PROFILE · PEPPERLEDGER
Thymosin Alpha-1 (Tα1)
Zadaxin (approved brand)
Type
Synthetic 28-amino-acid peptide — identical to the naturally occurring thymic hormone
Class
Immunomodulatory peptide — enhances T-cell function, NK cell activity, and dendritic cell maturation
Administration
Subcutaneous injection — typically 1.6 mg twice weekly
Half-life
~2 hours
Most studied use
Immune enhancement · Chronic infections · Cancer adjunct therapy · Sepsis · COVID-19 · Anti-aging via immune restoration
Regulatory status
Approved in 35+ countries (hepatitis B/C, cancer) · Not currently FDA-approved in the U.S. · Category 1 returnee 2026 · Research chemical in U.S.
Human evidence
Strong — large RCTs for hepatitis B/C; meta-analysis in sepsis; retrospective data for COVID-19; extensive real-world use in Asia and Europe
Preclinical evidence
Exceptional — 50+ years of research on thymic immunity
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is Thymosin Alpha-1?
Thymosin Alpha-1 is one of the most clinically established peptides in this space — with approval in over 35 countries, two decades of use in hepatitis B and C treatment, and a rapidly growing evidence base for sepsis, COVID-19, and cancer immunotherapy. It's not a research chemical in the way most compounds in this guide are. It's an approved pharmaceutical with a deep clinical track record — just not in the United States, where it remains off-label.
The biological context: the thymus gland produces Thymosin Alpha-1 naturally as part of T-cell education and maturation. The thymus begins involuting (shrinking and losing function) in the 20s and is largely non-functional by the 40s. As thymic function declines, so does the quality of adaptive immune surveillance — the system that detects and eliminates infected and cancerous cells. Thymosin Alpha-1 supplementation is essentially immune system restoration: replacing the thymic signal that declines with age.
The mechanism is primarily via T-helper cell (Th1) enhancement and dendritic cell maturation. Thymosin Alpha-1 shifts immune responses toward the Th1 pathway — the cell-mediated immune arm responsible for fighting viruses, intracellular bacteria, and cancer — while modulating the inflammatory response to prevent excessive cytokine production. This dual action is why it's been studied for both chronic infection and sepsis, which represent opposite immune problems.
The 2026 Category 1 reclassification means pharmacy-grade compounded Thymosin Alpha-1 is now accessible in the U.S. for the first time in a structured clinical pathway. That's a meaningful change in the access landscape for an immune compound with this depth of clinical evidence.
How it works
T-Cell Maturation and Th1 Enhancement
Thymosin Alpha-1 binds to Toll-like receptor 9 (TLR9) on dendritic cells, macrophages, and natural killer cells, activating MyD88-dependent signaling and NFκB. This drives dendritic cell maturation — improving their ability to present antigens to T cells and initiate adaptive immune responses. Downstream: enhanced CD4+ T-helper cell differentiation toward the Th1 phenotype, producing interferon-gamma (IFN-γ) and driving cell-mediated immunity against viruses, intracellular bacteria, and tumor cells.
NK Cell Activation and Inflammatory Modulation
Thymosin Alpha-1 increases natural killer cell activity and cytotoxicity — improving the innate immune layer that identifies and kills cells that have lost their 'self' markers (cancer cells, virus-infected cells). Critically, it also upregulates anti-inflammatory IL-10 alongside Th1 cytokines, dampening excessive cytokine storm while maintaining effective responses. This dual action explains why it reduces mortality in sepsis — a condition of pathological hyperinflammation — rather than making it worse.
Vaccine Response Enhancement
Thymosin Alpha-1 has been used as a vaccine adjuvant in multiple trials, significantly improving antibody titers and T-cell responses to vaccines in immunocompromised and elderly populations. The mechanism: better antigen presentation and T-cell priming due to enhanced dendritic cell maturation. This makes it particularly relevant for users whose vaccine responses may be suboptimal due to age or immune compromise.
What the research shows
HUMAN EVIDENCE
STUDYHepatology · 2005
Thymosin Alpha-1 for Hepatitis B — Multicenter RCT
Chan HL et al.
Randomized controlled trial. Thymosin Alpha-1 (1.6 mg SC twice weekly × 6 months) significantly increased HBeAg seroconversion in chronic hepatitis B. Basis for approval in multiple Asian countries.
Thymosin Alpha-1 Reduces Mortality in Severe COVID-19
Liu Y, Qin E, He Z et al.
85 severe COVID-19 patients. Thymosin Alpha-1: 11.11% mortality vs. 30.77% controls. Significant improvement in lymphocyte counts and inflammatory markers. Confirms the dual immune-enhancing and inflammation-modulating mechanism.
Thymosin Alpha-1 in Sepsis — Meta-Analysis of RCTs
Wu J, Zhou L, Liu J et al.
Meta-analysis of 6 RCTs in sepsis patients. Thymosin Alpha-1 significantly reduced 28-day mortality and ICU length of stay. Supports immune restoration in immunoparalysis — the immune exhaustion phase of sepsis.
STUDYAnnals of the New York Academy of Sciences · 2012
Thymosin Alpha-1 as Cancer Immunotherapy Adjuvant — Systematic Review
Garaci E et al.
Systematic review of Thymosin Alpha-1 as adjunct to chemotherapy and radiation. Improved immune parameters and quality of life across multiple cancer types. Establishes the immunotherapy adjuvant use case.
✓Approved in 35+ countries for hepatitis B and C — decades of real-world clinical use
✓Mortality reduction in severe COVID-19 (retrospective, Liu et al. 2021)
✓Mortality reduction in sepsis — meta-analysis of 6 RCTs (Wu et al. 2013)
✓NK cell and dendritic cell activation well-characterized
✓Vaccine response enhancement in immunocompromised populations
?UNCERTAIN
?Optimal dosing for healthy adults in longevity/maintenance context
?Long-term effects of sustained Thymosin Alpha-1 supplementation in healthy people
?Whether immune enhancement in healthy adults translates to cancer prevention
?Optimal cycling schedule for maintenance vs. acute infection use
?Head-to-head vs. other immunomodulatory compounds for healthy aging
What the community reports
Thymosin Alpha-1's community is smaller than BPC-157 or GLP-1 compounds but more clinically literate — many users come from an existing awareness of its approved use in other countries, or from oncology or infectious disease contexts. The compound attracts people thinking carefully about long-term immune health rather than short-term performance optimization.
—Reduced frequency and severity of illness — the most consistently reported effect over longer protocols; getting sick less often and recovering faster
—Improved energy and general sense of wellbeing — consistently present; likely reflects restoration of immune-metabolic signaling
—Post-illness or post-infection protocols — users recovering from COVID-19, Lyme, EBV, or chronic infections use Thymosin Alpha-1 as an immune restoration tool
—Cancer-adjacent use — users or family members with cancer using it as an adjunct alongside conventional treatment; consistent with the clinical trial evidence
—Vaccine enhancement: users time protocols around vaccinations to improve response; consistent with adjuvant trial evidence
—Side effects minimal — occasionally mild fatigue in the first 1–2 weeks; otherwise very well tolerated
Common misconceptions
"Thymosin Alpha-1 is not approved anywhere."
REALITY
Thymosin Alpha-1 (Zadaxin) is approved in over 35 countries including China, Italy, Philippines, and throughout Asia and Latin America. It has been used clinically for hepatitis B and C treatment for decades. It is not currently FDA-approved as a drug in the United States — but it is far from unapproved globally.
"Thymosin Alpha-1 just stimulates the immune system — more is always better."
REALITY
Thymosin Alpha-1 modulates rather than uniformly stimulates the immune system. Its mortality benefit in sepsis — a condition of pathological hyperinflammation — demonstrates that it can dampen excessive immune activation alongside enhancing targeted responses. This dual action is what makes it useful across both immunodeficiency and hyperinflammatory contexts.
"You need to be sick to benefit from Thymosin Alpha-1."
REALITY
Thymic involution begins in your 20s — by your 40s, your thymus is largely non-functional and Thymosin Alpha-1 production is minimal. This immune decline is a near-universal feature of human aging, not a disease state. Thymosin Alpha-1 supplementation as maintenance for healthy adults restoring age-related thymic decline is a legitimate use case even without active infection.
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I want to use Thymosin Alpha-1 for general immune maintenance. What protocol makes sense for a healthy 45-year-old?
For a healthy 45-year-old doing immune maintenance — not treating an active infection — the evidence framework is: the clinical trials used 1.6 mg twice weekly for 6 months in disease contexts (hepatitis B/C, cancer). For healthy aging maintenance, biohacker protocols extrapolate from this but typically use cycles rather than continuous dosing. Here's what the evidence-informed options look like. Standard maintenance cycle: 1.6 mg subcutaneous twice weekly for 8–12 weeks, then 4–8 weeks off. Run 2–3 cycles per year. This mirrors the dosing structure of the clinical trials while building in recovery periods appropriate for a healthy immune system rather than a chronically diseased one. The twice-weekly schedule is important — it's not once weekly. The half-life is ~2 hours, so consistent twice-weekly dosing maintains a regular immune signaling stimulus. At 45, the mechanistic case is real: thymic involution is well underway by your 40s — T-cell output from the thymus is a fraction of what it was at 20. The immune surveillance decline this produces is documented. Thymosin Alpha-1 replaces the signaling that's been lost. What to watch in the first cycle: the most commonly reported early effect is getting sick less often, which is a lagging indicator — you'll know the protocol is working when you go through the cycle without the seasonal illness you'd normally expect. Energy and general wellbeing are earlier signals. Important note: if you have any autoimmune condition or are on immunosuppressive medications, Thymosin Alpha-1's immune-enhancing effects require medical guidance before starting. It modulates rather than uniformly stimulates, but the interaction with autoimmune conditions isn't fully characterized. For a healthy 45-year-old without those factors, the twice-weekly maintenance protocol is the established starting point.
CONTINUE IN THE APP
Open PepperLedger to track your Thymosin Alpha-1 protocol →
Free to join. No credit card. Ask the Coach about your Tα1 protocol once you're in.
Free to join · No credit card · 23-day Pro trial included